{
    "clinical_study": {
        "@rank": "92298", 
        "brief_summary": {
            "textblock": "Review of the medical files of 69 patients with neuroendocrine tumours who were treated at\n      the CCI from January/10 - July/12 with Lutetium-177 DOTA-TATE under Health Canada's Special\n      Access Programme (SAP). Efficacy, safety, and other relevant data will be collected."
        }, 
        "brief_title": "Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and July 31, 2012", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neuroendocrine Tumors, NET", 
        "condition_browse": {
            "mesh_term": "Neuroendocrine Tumors"
        }, 
        "detailed_description": {
            "textblock": "Neuroendocrine tumours comprise a spectrum of rare neoplasms. Data analysis will be\n      conducted to obtain efficacy, safety, and other relevant data from each Lu-177 DOTA-TATE\n      treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female \u2265 14 - 90 years of age\n\n          -  Presence of histologically proven NET tumour(s)\n\n          -  Serum creatinine \u2264 150 \u00b5mol/L, and a measured GFR using plasma clearance of \u226550\n             mL/min\n\n          -  Haemoglobin concentration 5.5 mmol/L; WBC \u2265 2*109/L; platelets \u2265 100*109/L\n\n          -  Liver function tests (serum albumin, total bilirubin, ALT, AST and alkaline\n             phosphatase) \u2264 3X the upper limit of normal\n\n        Exclusion Criteria:\n\n          -  Potential for surgery with curative intent\n\n          -  Surgery, radiation therapy, cytotoxic chemotherapy, embolization or other\n             investigative therapy (interferons, mTOR inhibitors) within 12 weeks of enrollment\n\n          -  Known brain metastases unless these metastases have been treated and stabilized\n             (confirmed by CT) for \u2265 6 months prior to enrollment\n\n          -  Uncontrolled congestive heart failure\n\n          -  Receiving concomitant medications which decrease renal function\n\n          -  Uncontrolled diabetes mellitus\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "14 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Limited to those subjects with neuroendocrine tumors who received Lu-177 DOTA-TATE between\n        January 2010 and July 2012 at the Cross Cancer Institute."
            }
        }, 
        "enrollment": {
            "#text": "69", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763554", 
            "org_study_id": "REV-LUT-001"
        }, 
        "intervention": {
            "description": "Radiopharmaceutical solution for IV injection containing DOTA-TATE labeled with Lutetium-177. Standard dose is 5.5 GBq given as a single injection once every 8 to 12 weeks for 4 doses, followed by maintenance doses of 5.5 GBq every 6 months.", 
            "intervention_name": "Lu-177 DOTA-TATE", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lu-177", 
            "Lutetium-177", 
            "DOTA-TATE", 
            "Neuroendocrine tumors", 
            "radiopharmaceutical"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Edmonton", 
                    "country": "Canada", 
                    "state": "Alberta", 
                    "zip": "T6G 1Z2"
                }, 
                "name": "Cross Cancer Institute"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and July 31, 2012", 
        "overall_official": {
            "affiliation": "AHS Cancer Control Alberta", 
            "last_name": "Alexander McEwan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Data (Radioisotope and CT/MRI images, blood assays and Quality of Life Questionnaires, pre and post treatment) will be collected to determine tumor response of subjects with NET after treatment with Lu-177 DOTA-TATE.", 
            "measure": "Efficacy data on subjects with neuroendocrine tumours (NET) treated Lu-177 DOTA-TATE", 
            "safety_issue": "No", 
            "time_frame": "Retrospective data January 2010 - July 2012"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763554"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety data will include blood counts and chemistry, GFR and adverse events, pre and post treatment. Other data includes patient demographics.", 
            "measure": "Safety and other relevant information on subjects treated with Lu-177 DOTA-TATE", 
            "safety_issue": "No", 
            "time_frame": "Retrospective data January 2010 - July 2012"
        }, 
        "source": "AHS Cancer Control Alberta", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AHS Cancer Control Alberta", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}